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Abstract
Summary Guidelines for doctors managing osteoporosis in the Asia-Pacific region vary widely. We compared 18 guidelines for
similarities and differences in five key areas.We then used a structured consensus process to develop clinical standards of care for
the diagnosis and management of osteoporosis and for improving the quality of care.
Purpose Minimum clinical standards for assessment and management of osteoporosis are needed in the Asia-Pacific (AP) region
to inform clinical practice guidelines (CPGs) and to improve osteoporosis care. We present the framework of these clinical
standards and describe its development.
Methods We conducted a structured comparative analysis of existing CPGs in the AP region using a “5IQ”model (identification,
investigation, information, intervention, integration, and quality). One-hundred data elements were extracted from each guide-
line.We then employed a four-roundDelphi consensus process to structure the framework, identify key components of guidance,
and develop clinical care standards.
Results Eighteen guidelines were included. The 5IQ analysis demonstrated marked heterogeneity, notably in guidance on risk
factors, the use of biochemical markers, self-care information for patients, indications for osteoporosis treatment, use of fracture
risk assessment tools, and protocols for monitoring treatment. There was minimal guidance on long-term management plans or
on strategies and systems for clinical quality improvement. Twenty-nine APCO members participated in the Delphi process,
resulting in consensus on 16 clinical standards, with levels of attainment defined for those on identification and investigation of
fragility fractures, vertebral fracture assessment, and inclusion of quality metrics in guidelines.
Conclusion The 5IQ analysis confirmed previous anecdotal observations of marked heterogeneity of osteoporosis clinical
guidelines in the AP region. The Framework provides practical, clear, and feasible recommendations for osteoporosis care and
can be adapted for use in other such vastly diverse regions. Implementation of the standards is expected to significantly lessen the
global burden of osteoporosis.
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Introduction
Osteoporotic hip fractures among people in the Asia-Pacific
region are expected to increase dramatically due to population
aging, urbanization, and associated sedentary lifestyles [1]. Of
these factors, population aging represents the major challenge,
with the population of East Asia and the Pacific reported to be
aging more rapidly than any other region in history [2]. The
number of people who are 60 years and over in the Asia-
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Pacific region is predicted to triple between 2010 and 2050,
reaching an estimated 1.3 billion by 2050 [3]. The old-age
dependency ratio (OADR) is defined as the number of persons
aged 65 years or over (assumed to be economically inactive)
per 100 persons of working age (20 to 64 years). It provides an
index of the economic dependency associated with aging pop-
ulations and is expected to more than double in Eastern and
South-Eastern Asia between 2019 and 2050, rising from 18
older persons per 100 workers in 2019 to 43 in 2050. It is
predicted that Japan which was reported to have the highest
OADR in the world in 2019 will remain in first position in
2050, followed closely by several other countries and regions
in Eastern and South-Eastern Asia [4].
The Asia Pacific Consortium on Osteoporosis (APCO), a
non-partisan and apolitical organization, is comprised of oste-
oporosis experts drawn from a diverse range of clinical set-
tings, from low-, middle-, and high-income countries and re-
gions in the Asia-Pacific that have populations ranging be-
tween 4.8 million and 1.4 billion people.
APCO aims to develop regionally relevant, pragmatic, and
effective strategies for improving osteoporosis management
and reducing rates of fragility fractures. Adoption of such strat-
egies would lessen the burden of osteoporosis in this vast region
that accounts for more than 60% of the world’s population [5].
We have previously described APCO’s raison d’etre, concep-
tion and launch, vision, mission, and priority initiatives [6].
Launched inMay 2019, APCO’s first project was to develop
clear and concise standards for the screening, diagnosis, and
management of osteoporosis that are pan Asia-Pacific in their
reach. This decision was based on anecdotal observations that
existing guidelines for osteoporosis management within the
Asia-Pacific region are heterogeneous and vary widely in scope
and recommendations. Access to primary care services and
bone mineral density (BMD) assessment varies across jurisdic-
tions and regions, and little is known about adherence to current
guidelines in day-to-day clinical practice. APCO therefore de-
termined to (i) conduct a systematic, structured analysis of
existing guidelines in the Asia-Pacific region, (ii) identify re-
gionally relevant key guideline elements using a structured con-
sensus process, and (iii) develop, through a structured consen-
sus process, feasible regional clinical care standards that will
both support clinical improvement initiatives and provide a
framework for the development of new national clinical prac-
tice guidelines or the revision of existing ones.
This article describes the process by which, on a back-
ground of the existing guidelines in the Asia-Pacific region,
APCO members developed and endorsed a new set of mini-
mum standards of care that can be adapted and adopted across
the region.We also highlight emerging themes in osteoporosis
that have not yet been incorporated into any of the existing
guidelines, but have enormous implications and potential to
change the landscape of osteoporosis treatment.
Methods
A framework of minimum clinical care standards (the
Framework) was developed in two stages: (i) a detailed com-
parative analysis of osteoporosis clinical practice guidelines in
the Asia-Pacific region, and (ii) a structured consensus process
to draft the standards.
Comparative analysis of osteoporosis guidelines in
the Asia-Pacific region
Existing national or regional clinical practice guidelines and/
or standards of care were identified through a survey among
APCO members. A structured template was developed to fa-
cilitate standardized identification of guideline components.
The template was based on the “5IQ” model (Table 1), mod-
ifications of which have been used to develop clinical stan-
dards for fracture liaison services (FLSs) in Japan [7], New
Zealand [8], and in the UK [9].
For each guideline, we identified the format in which the
recommendations/information were provided and extracted
details of these parameters. One hundred data elements
were extracted from each guideline (the template used for
extracting data from clinical practice guidelines is provided
in Appendix 1):
& Background information (8 elements).
& Case identification (34 elements). Checklists of risk fac-
tors were derived from a recent review examining case-
finding strategies from a global perspective [10].
& Investigation (21 elements).
& Advice and education for patients (5 elements).
& Interventions (28 elements), including indications for
treatment, treatments, recommendations for follow-up
and duration of treatment, and recommendations for
falls prevention. Given the complexity of indica-
tions, a coding system was created to allow quanti-
tative comparison. Commentary on treatment/
supplementation with calcium and/or vitamin D was
also coded to compare the proportions of guidelines
that recommended these options as active therapy, as
d is t inc t f rom adjunc t ive the rapy a longs ide
osteoporosis-specific treatments.
& Strategies for long-term management and integration of
osteoporosis care into the health system (2 elements).
& Strategies to promote the quality of clinical care (2
elements).
Findings were analyzed separately for guidelines published
between 2015 and 2020 (“newer guidelines”) and those pub-
lished before 2015 (“older guidelines”).
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Consensus process for developing the clinical care
standards framework
A four-round Delphi process was adopted to develop stan-
dards of care for osteoporosis risk assessment, diagnosis,
and management that are appropriate for the Asia Pacific re-
gion. The Delphi method has been widely used for establish-
ing clinical consensus on other clinical conditions [11]. This
structured approach ensures that the opinions of participants
are equally considered, and it is particularly useful for geo-
graphically diverse groups like APCO. The Delphi process
was conducted through online questionnaires.
Round 1
APCO members were invited to determine which aspects of
care required clinical standards to be developed, based on a
list informed by the findings of the 5IQ comparative analysis.
The questionnaire included 32 questions under three domains
(Appendix 2):
& Domain 1. What are the notable findings from the 5IQ
Comparative analysis of osteoporosis clinical guidelines
from across the Asia Pacific region? Participants were
referred to specific sections within the analysis report
and invited to identify important findings.
& Domain 2: How should the Framework be structured?
Participants were asked to indicate how the Framework
should be structured, including whether levels of attain-
ment should be included for clinical standards to serve as
potential quality performance indicators.
& Domain 3. What clinical standards are required? For
each of 21 key elements identified in the 5IQ analysis
of Asia-Pacific clinical practice guidelines, partici-
pants were asked their opinion on the importance of
its inclusion as a clinical standard (5-point scale from
“extremely important” to “not at all important,” with
optional free text comments). Consensus was defined
as a ranking of “extremely important” or “very impor-
tant” by at least 75% of respondents. Participants were
also invited to make any general comments on devel-
opment of the Framework.
Round 2
Members were asked to express their agreement (or not) with the
wording of 16 draft clinical standards, of which several included
proposed wording on levels of attainment (5-point scale from
“strongly agree” to “strongly disagree”). For each draft standard,
members were also invited to propose alternative wording or
make comments. Consensuswas defined as a ranking of “strong-
ly agree” or “agree” by at least 75% of respondents.
Round 3
The wording of clinical standards and levels of attainment was
amended, based on the results of Round 2. APCO members
were invited to approve amendments (yes/no options).
Consensus was defined as a “yes” response to a proposed
rewording by at least 75% of respondents.
Round 4
A fourth round was conducted after some of the standards and
levels of attainment were again reworded for clarity and pre-
cision without changing their intent. The minor amendments
to the wording of the standards, with commentary itemizing
each change, were sent to the APCO members who had par-
ticipated in one or more of the previous Delphi rounds.
Members were instructed to reply to the Chairperson by a
stipulated date if they had any objection to the rewording of
the standards.
Results
The analysis included 18 guidelines (Table 2) from the fol-
lowing regions: Australia [12], China (three guidelines)
[13–15], Chinese Taipei [16], Hong Kong Special
Administrative Region of the People’s Republic of China
(SAR) [17], India (two guidelines) [18, 19], Indonesia [20],
Japan [21], Malaysia [22], Myanmar [23], New Zealand [24],
the Philippines [25], Singapore [26], South Korea [27],
Thailand [28], and Vietnam [29]. Of these, 14 (78%) were
published between 2015 and 2020. Two-thirds of the
Table 1 The 5IQ model for
analyzing the content of clinical
practice guidelines
Component Description
Identification A statement of which individuals should be identified
Investigation A description of the types of investigations that will be undertaken
Information A description of the types of information that will be provided to the individual
Intervention A description of pharmacological interventions and falls prevention
Integration A statement on the need for integration between primary and secondary care
Quality A description of professional development, audit, and peer-review activities
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guidelines did not specify a date for planned revision. Six
stated that an update within 3–5 years was planned.
Eleven of the guidelines were available in English. A pro-
fessional medical translation agency was commissioned to
translate four guidelines from Chinese, and the Vietnamese
guideline was translated by an APCO member. Data extrac-
tion for the Japanese guidelines was undertaken by an APCO
member and that for the Korean guideline was undertaken by
a native speaker who was also an osteoporosis clinician.
Identification
Risk factors/indications for assessment and evaluation
Fifteen of the 18 guidelines cited risk factors separately for
men and women, two guidelines for women only, and another
did not state the sex to which cited risk factors applied.
The most commonly cited risk factors for osteoporosis (cit-
ed in at least half the guidelines) were excessive alcohol con-
sumption (17 guidelines), a family history of osteoporosis
and/or fractures (17 guidelines), smoking (17 guidelines),
low body mass index (BMI)/weight (16 guidelines), height
loss (13 guidelines), age over 70 years (13 guidelines), and
early menopause (12 guidelines).
A range of other age thresholds for increased risk was also
identified, with several citing one or more of the following:
adults (four guidelines), postmenopausal women (three guide-
lines), 50 years and above (two guidelines), 60 years and above
(one guideline), and 65 years and above in men (one guideline).
All 18 guidelines cited a history of fragility fracture as a
risk factor for subsequent fracture. Thirteen of 18 guidelines
specified the type of fragility fractures, most commonly spine,
hip, proximal femur, wrist, forearm, distal radius, humerus,
pelvis, and ribs. In the context of case identification, one
Table 2 Osteoporosis management clinical practice guidance documents included in the 5IQ analysis
Country or
region
Organization(s) Name of guideline
Australia Osteoporosis Australia The Royal Australian College
of General Practitioners
Osteoporosis prevention, diagnosis and management in
postmenopausal women and men over 50 years of age [1]
China Osteoporosis and Bone Mineral Disease Branch of Chinese
Medical Association
Guidelines for the diagnosis and treatment of primary
osteoporosis [2]
China Osteoporosis Society of China Association of Gerontology and
Geriatrics
2018 China guideline for the diagnosis and treatment of senile
osteoporosis [3]
China Osteoporosis Group, Orthopedic Branch, Chinese Medical
Association
Guidelines for the diagnosis and treatment of osteoporotic
fractures [4]
Hong Kong SAR The Osteoporosis Society of Hong Kong OSHK guideline for clinical management of postmenopausal
osteoporosis in Hong Kong [5]
Chinese Taipei Taiwanese Osteoporosis Association Consensus and guidelines for the prevention and treatment of
adult osteoporosis in Taiwan [6]
India Indian Menopause Society Clinical practice guidelines on postmenopausal osteoporosis:
An executive summary and recommendations [7]
India Indian Society for Bone and Mineral Research Indian Society for Bone and Mineral Research guidelines
2020 [8]
Indonesia Indonesian Osteoporosis Association (Perhimpunan
Osteoporosis Indonesia)
Summary of the Indonesian guidelines for diagnosis and
management of osteoporosis [9]
Japan Japan Osteoporosis Society The Japanese Society for Bone and
Mineral Research Japan Osteoporosis Foundation
Japanese 2015 guidelines for the prevention and treatment of
osteoporosis [10]
Malaysia Malaysian Osteoporosis Society Academy of Medicine
Ministry of Health Malaysia
Clinical guidance on management of osteoporosis [11]
Myanmar Myanmar Society of Endocrinology and Metabolism Myanmar clinical practice guidelines for osteoporosis [12]
New Zealand Osteoporosis New Zealand Guidance on the diagnosis and management of osteoporosis in
New Zealand [13]
Philippines Osteoporosis Society of Philippines Foundation Philippine
Orthopedic Association
Consensus statements on osteoporosis diagnosis, prevention,
and management in the Philippines [14]
Singapore Agency for Care Effectiveness, Ministry of Health
Singapore
Appropriate care guide: osteoporosis identification and
management in primary care [15]
South Korea Korean Society for Bone and Mineral Research KSBMR Physician's Guide for Osteoporosis [16]
Thailand Thai Osteoporosis Foundation Thai Osteoporosis Foundation (TOPF) position statements on
management of osteoporosis [17]
Vietnam Vietnam Rheumatology Association Guidelines for the diagnosis and treatment of osteoporosis [18]
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guideline from China mentioned the importance of FLSs to
promote multidisciplinary joint diagnosis and treatment.
While all the guidelines identified glucocorticoid treatment
as being associated with bone loss and/or increased fracture
risk, the lists of other medicines associated with bone loss
varied between guidelines. More than half of the guidelines
also identified users of androgen deprivation therapy (11/18
guidelines), anticoagulants (9/18 guidelines), anticonvulsants
(10/18 guidelines), and aromatase inhibitors (11/18 guide-
lines) as at-risk groups. Other medications that were identified
included proton pump inhibitors, thiazolidinediones, and se-
lective serotonin reuptake inhibitors.
Themedical conditions most frequently cited as risk factors
were rheumatoid arthritis, malabsorption, hyperthyroidism,
and multiple myeloma. Diabetes was noted as a risk factor
in 10 of 14 (71%) of the newer guidelines, compared with
none of the older guidelines.
Investigation
Biochemical tests
The extent of commentary on assays for bone turnover
markers and other biochemical parameters varied consider-
ably between the guidelines. Some guidelines only briefly
mentioned biochemical tests in the evaluation of osteoporosis,
while others provided detailed guidance. Total procollagen
type 1 N-terminal propeptide (P1NP) was the most frequently
recommended bone turnover marker (16/18 guidelines). Other
laboratory tests that were commonly recommended in the
guidelines included calcium, alkaline phosphatase, 25-
hydroxyvitamin D, creatinine, urinary N-telopeptide
(uNTX), parathyroid hormone (PTH), and osteocalcin.
Risk assessment tools
The FRAX® fracture risk assessment tool [30] was by far the
most commonly recommended risk assessment tool (17/18
guidelines), followed by the Osteoporosis Self-Assessment
Tool for Asians (OSTA) (11/18 guidelines) [31]. Some newer
guidelines also recommended a range of other tools: the
Garvan nomogram [32] (three guidelines), IOF Risk Check
(“one-minute osteoporosis risk test”)[33] (three guidelines),
the Khon Kaen Osteoporosis Study (KKOS) scoring system
[34] (one guideline), the Male Osteoporosis Risk Estimation
Score (MORES) [35] (1 guideline), QFracture algorithm [36,
37] (one guideline), and Simple Calculated Osteoporosis Risk
Estimation (SCORE) [38] (one guideline).
Vertebral fracture assessment
All 18 guidelines mentioned the use of radiography to identify
vertebral fractures, with some directly recommending x-ray of
the thoracic and lumbar spine, some advising when it should
be considered, and one simply noting that bone loss and
healing fractures may be evident on radiographs. Dual-
energy x-ray absorptiometry (DXA)–based vertebral fracture
assessment (VFA) was mentioned in eight guidelines, with
guidance ranging from just statements of its existence or sim-
ple advice to consider DXA for identifying fractures, to the
inclusion of DXA-identified fractures in treatment indications.
Falls risk assessment
Thirteen of 18 guidelines referred to the importance of
falls risk assessment. The degree of detail varied widely
with some amount of detail specified in the guidelines
from Australia, China, Hong Kong SAR, Chinese
Taipei, India, Malaysia, Japan, Thailand, and New
Zealand. Some guidelines emphasized that falls risk as-
sessment should be conducted routinely in all older adults
(Australia), while others discussed falls risk assessment
for patients known to be at risk of fragility fractures or
with a history of fracture. One of the Chinese guidelines
recommended that attention should be paid to the evalua-
tion of fall-related risk factors in elderly patients with
osteoporosis. Some guidelines recommended certain as-
pects of assessment, such as muscle strength and balance,
while the Hong Kong SAR and one of the other Chinese
guidelines provided comprehensive guidance on specific
medical and environmental risk factors to consider when
performing the assessment. Some mentioned strategies or
structured tools for performing falls risk assessment
(Thailand).
Specialist assessment
Ten of 18 guidelines recommended specialist referral for as-
sessment in certain clinical scenarios. Four recommended that
any patient with fragility fractures or osteoporosis should be
referred for specialist assessment or care. Other specified sce-
narios included fracture or persistent loss of BMD despite
treatment, complex conditions, problems considered “diffi-
cult” or beyond the scope of primary care, secondary osteo-
porosis, severe or unusual presentation, when first-line treat-
ments were contraindicated or not tolerated, when assessment
for specialized treatments is needed (e.g., teriparatide or long-
term estrogen therapy), and when bone densitometry is not
available.
Information
There was considerable variation in the extent to which the
various guidelines recommended that specific information
should be provided to patients.
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Calcium intake and exercise
All 18 guidelines recommended that information should be
provided on calcium intake, and 17 recommended providing
information on exercise.
Sun exposure
Ten out of 18 guidelines (including one older guideline) rec-
ommended that patients should be provided with information
on sun exposure to maintain healthy vitamin D levels.
Fracture risk
Only seven out of 18 guidelines (all newer guidelines) recom-
mended that patients should be given information about the
link between osteoporosis and fracture risk.
Intervention
Indications for treatment
All 18 guidelines cited BMD T-score of ≤ − 2.5 standard
deviations (SD) as an indication for treatment. The reference
database to be used to delineate T-scores was specified in only
a minority of the guidelines. A broad range of other indica-
tions for treatment were cited in the various guidelines, with
each guideline typically featuring three or four of a total of 14
indications identified.
Most guidelines cited hip and vertebral fractures as an in-
dication for treatment. Fifteen of the 17 guidelines that includ-
ed hip fracture as an indication for treatment, and all 17 guide-
lines that included vertebral fracture as an indication for treat-
ment, stated that BMD testing was not required to initiate
treatment. Of the 15 guidelines that included non-hip, non-
vertebral fracture as an indication for treatment initiation, nine
suggested that BMD testing was not necessary prior.
Thirteen guidelines mentioned or recommended treatment
thresholds based on FRAX® probabilities. Six guidelines cited
the threshold recommended by the US National Osteoporosis
Foundation guidelines [39] (BMD T-Score in the osteopenic
range, in combination with a FRAX® 10-year probability of
≥ 3% for hip fracture risk or ≥ 20% for major osteoporotic
fracture risk). Of these, only two (the Malaysian guideline and
one of the guidelines from China) explicitly recommended that
this threshold should be adopted for their local target popula-
tion. The Hong Kong SAR guideline stated that the US criteria
were provided for clinical guidance only and that treatment
decisions should consider individual patient factors. Other
guidelines cited the US treatment threshold as an example or
in commentary, without further interpretation.
Some guidelines provided guidance on the logistics and
limitations of applying FRAX® to local populations. One of
the guidelines from China [15] stated that the current predic-
tion results may underestimate fracture risk in the Chinese
population. Several others recommended the use of popula-
tion specific FRAX® algorithms (e.g., Hong Kong SAR,
India, Singapore, Thailand, Vietnam).
Osteopenia in combination with other criteria (e.g., pres-
ence of risk factors, risk scores, ≥ 10 years post menopause)
was included in several guidelines.
Pharmacological treatment options
Less than one-third of guidelines classified treatment options
as first line, second line, and third line. All guidelines recom-
mended bisphosphonates (oral and intravenous) and raloxi-
fene as treatment options for osteoporosis. Most guidelines
also recommended denosumab, teriparatide, and hormone re-
placement therapy (HRT). Predictably, the recently intro-
duced treatments, abaloparatide and romosozumab, were rec-
ommended in only two newer guidelines (India and Korea).
Adjunctive treatments
Calcium and vitamin D were recommended as adjunctive
therapies more often than as active treatments. That calcium
was not a treatment option was explicitly stated in less than
half of the guidelines.
Adverse effects
The volume of commentary on potential adverse effects of
osteoporosis treatments varied considerably between guide-
lines. Eleven of 18 guidelines provided information on ad-
verse effects associated with all or several classes of anti-
osteoporosis agents.
Monitoring therapeutic response and long-term follow-up
Almost all the guidelines provided information on the
role of repeated measurements of BMD and biochemical
markers of bone turnover in monitoring. Some specified
intervals for repeating tests (Table 3). Overall, there was
limited guidance on making long-term management
plans and providing them to the patient or primary care
provider. Only two guidelines explicitly stated the need
for a long-term plan, while 8 others implied the need
for such planning.
Treatment duration
Duration of treatment was specified in 13 guidelines and
discussed very generally in two others. Most guidelines
advised using bisphosphonates for 3–5 years before
reassessing to determine whether to continue or
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discontinue with observation (“drug holiday”), based on
assessment of treatment response and fracture risk.
Another guideline recommended continuing bisphospho-
nate therapy for 5–10 years before reconsideration.
Several guidelines gave detailed guidance based on risk
assessment. Three guidelines recommended that
teriparatide treatment should not exceed 2 years, while
one guideline recommended 3 years of treatment with
teriparatide. Of the four guidelines that discussed HRT
and mentioned initiation of, and duration of therapy
with it, one (Australia) recommended that its long-term
use is not recommended. The Hong Kong SAR guide-
line recommended that patients should be adequately
counselled on the risks and benefits of long-term use
(beyond 3-5 years for combined estrogen-progesterone
therapy and beyond 7 years for Estrogen alone therapy).
The Indian Menopause Society guideline recommended
it as first line therapy for women with menopausal
symptoms for up to 10 years after menopause and spe-
cifically stated that HRT should not be started solely for
bone protection after 10 years of menopause. The guid-
ance from Singapore specified that menopausal hormone
Table 3 Recommendations for timing of bone densitometry in follow-up
Guideline Mode First test (if stated separately) Intervals for repeat tests (if stated)
Australia DXA – ≥ 2 years when considering efficacy of
treatment, risk assessment or decision
to change or interrupt treatment
Every 1 year in patients at high risk
China
(Orthopedic)
DXA 1 year after starting treatment –
China (CSOBMR) Unspecified (bone density measurement) 1 year after starting or changing treatment Every 1–2 years when effect has stabilized
China (Geriatrics) DXA or QCT (if available) – Unspecified
(Monitor efficacy)
Biochemical markers of bone turnover – Every 3–6 months
Chinese Taipei DXA 2 years after starting treatment




Hong Kong SAR BMD (not specified) 1–2 years after starting treatment in
patients treated with antiresorptive
treatment
1 year after starting
treatment in patients treated with
bone-forming agents
2–3 after therapeutic effect established
India (IMS) DXA (use same DXA machine) – 2 years
India (ISBMR) DXA (if available) – 2 years
Indonesia BMD (not specified) – 1–2 to evaluate treatment response (defined
as stable over 1 year)
Japan BMD (not specified) 1 year after starting treatment > 1 year (unspecified)—after 1 year’s
treatment with bisphosphonates, intervals
longer than 1 year needed to see change
in BMD
Malaysia DXA Not specified Not specified
(Monitoring the effect of therapy)
New Zealand BMD (not specified) 4–5 years after starting treatment to
determine whether bisphosphonates
treatment should continue
≥ 3 years (intervals < 3 years not
recommended in most patients)
Singapore DXA 1–2 years after starting treatment to
establish clinical effectiveness
Every 2–3 years after clinical effectiveness
established
South Korea DXA – Every 1 year until normal BMD
(T-score > − 1.0)2 years after previous
normal BMD
Thailand DXA (Use same axial DXA analyzer) – > 1 year
Vietnam Not specified 1–2 years 1–2 years
BMD bone mineral density, DXA dual-energy X-ray absorptiometry, QCT quantitative computed tomography
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therapy can be considered for prevention of osteoporosis
and fragility fractures in women who experience early
menopause and that it can be continued until the normal
age of menopause unless contraindicated. Of the two
guidelines that mentioned duration of denosumab thera-
py, one recommended long-term use and the other rec-
ommended reevaluation of fracture risk after 5–10 years.
Adherence
Nine guidelines made specific recommendations on assessing
and encouraging adherence.
Falls prevention programs
Five guidelines made specific recommendations for referral to
falls prevention programs. A further three guidelines provided
detailed commentary on falls risk assessment.
Integration
Overall, there was limited commentary on the need to develop
a long-term management plan and provide it to the primary
care provider and/or the patient. Only two guidelines explic-
itly referred to the need for a long-term care plan, while eight
others implied that this was needed.
Though not specifically referring to the concept of integra-
tion and long-term planning, one guideline (South Korea) rec-
ommended the development of a secondary fracture preven-
tion program that would be practical and suitable for their
country to reduce re-fracture rates.
Quality
In general, there was limited commentary on audit of
practice against standards, or on continuing professional
development and learning that is required. One guideline
(Chinese Taipei) advocated benchmarking the perfor-
mance of FLSs against the IOF Capture the Fracture®
best-practice framework standards [40]. Another (New
Zealand) recommended auditing against national clinical
standards for FLSs. One guideline (Malaysia) included an
audit question to assess post-hip fracture osteoporosis
care. The need for a national hip fracture registry was
noted in one guideline (India). Several guidelines identi-
fied dissemination of clinical practice guidelines and on-
going continuing professional development as priorities
for healthcare professionals involved in the provision of
care for people living with osteoporosis.
Conclusions of the comparative analysis of existing
guidelines
The 5IQ analysis confirmed previous anecdotal findings
of marked heterogeneity among clinical practice guide-
lines for osteoporosis in the Asia-Pacific region—
notably in guidance on risk factors, the use of biochemical
bone turnover markers, self-care information for patients,
indications for osteoporosis treatment, the use of fracture
risk assessment tools, and protocols for monitoring treat-
ment. Minimal guidance was provided on long-term man-
agement plans. Few mentioned strategies and systems for
ensuring clinical quality improvement.
Outcomes of the Delphi process
The surveys were sent to current APCO members (n = 39), of
whom 29 participated in one or more of the four rounds.
Respondents were drawn from 18 countries/regions viz
Australia (3), Brunei (1), China (1), Hong Kong SAR (2),
Chinese Taipei (1), India (3), Japan (1), Korea (1), Malaysia
(2), Myanmar (1), Nepal (1), New Zealand (3), Pakistan (1),
Philippines (1), Singapore (2), Sri Lanka (1), Thailand (2), and
Vietnam (1) and from the International Osteoporosis
Foundation (1).
Round 1
Consensus was reached on the inclusion of clinical standards
on the following components (i.e., ≥ 75% rated its inclusion as
important or extremely important (Table 4)):
& Identification of individuals with fragility fractures
& Identification of individuals with common risk factors for
osteoporosis, such as age 70 years or above, early meno-
pause, excessive alcohol intake, family history, height
loss, low body mass index/weight, prolonged immobility,
smoking
& Identification of individuals who take medicines associat-
ed with bone loss and/or increased fracture risk
& Identification of individuals with conditions associated
with bone loss and/or increased fracture risk
& Use of risk assessment tools
& Vertebral fracture assessment
& Falls risk assessment
& Information provided to patients on self-care, such as cal-
cium intake, sun exposure, the relationship between oste-
oporosis and fracture risk, exercise
& Indications for treatment to include hip fracture, vertebral
fracture, and non-hip non-vertebral facture
& Recommendations for pharmacological interventions for
specific patient subgroups
& Recommendations for nonpharmacological interventions
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& Description of side effects of pharmacological treatments
& Monitoring of pharmacological treatment
& Duration of pharmacological treatment
& Adherence to pharmacological treatment
& Provision of long-term management plans to patients and/
or primary care providers
& Quality metrics for adherence to guideline-based care.
Sixteen standards were drafted based on this consen-
sus. Although the initial intention was to draft levels of
attainment for each standard, only a few standards proved
amenable to this approach after collating respondents’
comments on priority rankings and levels of attainment.
Levels of attainment were therefore drafted initially for
five standards viz for those on (a) identification of fragil-
ity fractures, (b) identification of patients with common
risk factors, (c) investigation of vertebral fractures, (d)
assessment of adherence to pharmacological treatment,
and (e) quality metrics to assess clinical adherence to
guidelines. Each of these five standards had three levels
of attainment, stratified according to degree of difficulty
or feasibility of implementation.
Round 2
Consensus was reached (i.e., ≥ 75% of respondents strongly
agreed or agreed) on the wording of all 16 standards (Fig. 1).
Agreement was unanimous or nearly so (> 90% agreement)
for the wording of draft standards on:
Table 4 Delphi round 1 responses















Fragility fracture 22 3 0 0 0 Yes (100%)
Risk factors for osteoporosis 12 10 2 0 0 Yes (92%)
Medicines associated with bone
loss/fracture risk
7 15 3 0 0 Yes (88%)
Medical conditions associated
with bone loss/fracture risk
5 16 4 0 0 Yes (84%)
Investigation
Biochemistry 5 11 8 1 0 No
BMD testing 8 9 8 0 0 No
Risk assessment tools 12 9 3 1 0 Yes (84%)
Vertebral fracture assessment 14 5 4 1 0 Yes (79%)
Falls risk assessment 9 13 3 0 0 Yes (88%)
Specialist referral 4 11 8 2 0 No
Information for patients 14 7 4 0 0 Yes (84%)
Intervention
Indications—see Table 5 N/A
Pharmacological 10 12 3 0 0 Yes (88%)
Non-pharmacological 4 16 4 1 0 Yes (80%)
Side effects 6 15 3 1 0 Yes (84%)
Monitoring effect 11 11 3 0 0 Yes (88%)
Duration 13 8 4 0 0 Yes (84%)
Adherence 8 12 3 2 0 Yes (80%)
Falls programs 5 13 6 0 0 No
Integration




10 12 2 1 0 Yes (88%)
Respondents’ priority ratings for each of the key components identified in existing clinical practice guidelines. Consensus was defined as a rating of
extremely important or very important by at least 75% of respondents
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& Proactive case identification based on medicines associat-
ed with bone loss/increased fracture risk
& The use of country-specific fracture risk assessment tools,
vertebral fracture assessment, and falls risk assessment
& Duration of pharmacological treatment and adherence to
pharmacological treatment
& Long-term management plans
& Metrics for adherence to guidelines
Diversity of opinion was greatest for the wording of the
draft standard on proactive case identification based on
Fig. 1 Delphi second-round
consensus on wording of
standards. The proportion of
respondents who voted “strongly
agree” or “agree” on the wording
of 16 draft clinical practice
standards




Indications Selected (n) Consensus (% rating as
extremely or very
important, i.e., ≥ 75%)Yes No
Hip fracture 24 1 Yes (96%)
Vertebral fracture 24 1 Yes (96%)
Non-hip non-vertebral fracture 20 5 Yes (80%)
BMD T-score ≤ − 2.5 SD 18 7 No
Osteopenia + FRAX® ≥ 3% hip or ≥ 20% MOF 11 14 No
Osteopenia + RFs or eligible by OSTA or SCORE 7 18 No
Osteopenia + ≥ 10 years post menopause 3 23 No
FRAX® or Garvan ≥ 3% hip or ≥ 20% MOF 9 16 No
Eligible by OSTA, MORES, or SCORE 1 24 No
QCT 2 23 No
Height loss > 4 cm 11 14 No
Androgen deprivation therapy 10 6 No
Aromatase inhibitor treatment 9 16 No
Glucocorticoid treatment 17 8 No
Country-specific thresholds 14 11 No
BMD bone mineral density,MORESMale Osteoporosis Risk Estimation Score, OSTA Self-Assessment Tool for
Asians, SCORE Simple Calculated Osteoporosis Risk Estimation, QCT quantitative computed tomography
The percentage of APCO member respondents who rated each of the proposed indications for initiating osteo-
porosis treatment identified in existing clinical practice guidelines, as extremely or very important for inclusion in
APCO clinical practice standard 9
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common risk factors, although consensus was reached. The
volume of comments (excluding minor editing suggestions)
was highest for the standards on, medicines associated with
risk, assessment of vertebral fractures, intervention thresholds
for osteoporosis-specific therapies (Table 5), and assessment
of adherence to pharmacological therapies.
Draft standards from which levels of attainment were subse-
quently removed Of the five standards that had levels of at-
tainment drafted, consensus was reached on the wording of all
except those on identification of patients with common risk
factors (69.6% voted “strongly agree” or “agree”). For this
standard, the proposed levels were as follows: Level 1—
identification of individuals with common risk factors to in-
clude alcohol intake of ≥ 2 units per day, a family history of
osteoporosis or fragility fracture, BMI ≤ 20 kg/m2, or a history
of smoking. Level 2—identification of individuals with Level
1 common risk factors plus age ≥ 70 years and/or height loss
of ≥ 4 cm compared to maximum height as a young adult.
Level 3—identification of individuals with Level 1 and 2
common risk factors plus early menopause (defined as occur-
ring before 45 years) and/or prolonged immobility. Issues not-
ed by respondents for this included the difficulty of
implementing these levels of attainment and the omission of
particular risk factors (prolonged glucocorticoid use and falls
risk). There were also concerns about defining levels accord-
ing to numbers of risk factors, with suggestions that the levels
should instead represent increasing percentages of at-risk pa-
tients identified, or be defined by the approach to case-finding,
e.g., whether at-risk individuals are identified systematically
or otherwise. Given the significant discordance among the
participants, it was therefore decided by consensus that this
standard would not be amenable to levels of attainment.
The threshold for consensus (75%) was reached on the
wording of draft attainment levels for the standard on assess-
ment of adherence to pharmacological therapy, but levels were
not retained after several respondents queried the selection of
cut-points and the feasibility of implementing the levels.
Thus, out of the five standards that were originally drafted
with levels of attainment, we retained the levels in only three
of them. These three standards were on (a) identification of
fragility fractures, (b) investigation of vertebral fractures, and
(c) quality metrics to assess clinical adherence to guidelines.
Members proposed alternative wordings for several stan-
dards and levels of attainment, including several of those that
reached consensus. The chairperson and project manager an-
alyzed the suggestions and drafted amendments.
Round 3
Consensus was achieved on all the proposed amendments,
involving six standards, and levels of attainment for two
standards. At the end of this round, consensus had been
reached on the final Framework of minimum clinical
standards.
Round 4
There were no objections to the minor amendments proposed to
improve clarity and precision of the wording of some of the
standards.
APCO Framework
Clinical standard 1 Men and women who sustain a fragility
fracture should be systematically and proactively identified to
undergo assessment of bone health and, where appropriate, falls
risk.
Levels of attainment for clinical standard 1:
& Level 1: Individuals who sustain hip fractures should be
identified.
& Level 2: Individuals who sustain hip and/or clinical verte-
bral fractures should be identified.
& Level 3: Individuals who sustain hip, clinical and/or mor-
phometric vertebral, and/or non-hip, non-vertebral major
osteoporotic fractures should be identified.
Clinical standard 2Men and women with common risk factors
for osteoporosis should be proactively identified to undergo
assessment of bone health and, where appropriate, falls risk. A
sex-specific age threshold for assessment should be deter-
mined for each country or region and should be included in
new or revised osteoporosis clinical guidelines.
Clinical standard 3 Men and women who take medicines that
are associated with bone loss and/or increased fracture risk
should be proactively identified to undergo assessment of
bone health and, where appropriate, falls risk. A commentary
should be included in new or revised osteoporosis clinical
guidelines to highlight commonly used medicines that are
associated with bone loss and/or increased fracture risk.
Clinical standard 4 Men and women who have conditions
associated with bone loss and/or increased fracture risk should
be proactively identified to undergo assessment of bone
health. A commentary should be included in new or revised
osteoporosis clinical guidelines to highlight common preva-
lent conditions in the country or region.
Clinical standard 5 The use of country-specific (if available)
fracture risk assessment tools (e.g., FRAX®, Garvan, etc.) or
osteoporosis screening tools (e.g., OSTA) should be a
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standard component of investigation of an individual’s bone
health and prediction of future fracture risk and/or osteoporo-
sis risk.
Clinical standard 6 Assessment for presence of vertebral
fracture(s) either by X-ray (or other radiological inves-
tigations such as CT or MRI), or by DXA-based VFA
should be a standard component of investigation of os-
teoporosis and prediction of future fracture risk.
Levels of attainment for clinical standard 6:
& Level 1: Individuals presenting with clinical verte-
bral fractures should undergo assessment for
osteoporosis.
& Level 2: Individuals with incidentally detected vertebral
fractures on X-ray and/or other radiological investigations
should be assessed for osteoporosis.
& Level 3: Individuals being assessed for osteoporosis
should undergo spinal imaging with X-ray or other appro-
priate radiological modalities, or with DXA-based VFA.
Clinical standard 7 A falls risk assessment should be a stan-
dard component of investigation of an individual’s future frac-
ture risk.
Clinical standard 8 In order to engage individuals in their own
care, information should be provided on calcium and vitamin
D intake, sun exposure, exercise, and the relationship between
osteoporosis and fracture risk.
Clinical standard 9 The decision to treat with osteoporosis-
specific therapies and the choice of therapy should be in-
formed as much as possible by country-specific and cost-
effective intervention thresholds. Intervention thresholds that
can be considered include:
& History of fragility fracture
& BMD T-score ≤ − 2.5 S.D.
& High fracture risk as assessed by country-specific inter-
vention thresholds
Clinical standard 10 New or revised osteoporosis clinical
guidelines should include a commentary on the common side
effects of pharmacological treatments that are recommended
in the guidelines.
Clinical standard 11 New or revised osteoporosis clinical
guidelines should provide a commentary on monitoring of
pharmacological treatments. This could include, e.g., the role
of biochemical markers of bone turnover and bone mineral
density measurement.
Clinical standard 12 New or revised osteoporosis clinical
guidelines should provide a commentary on the duration of
pharmacological treatments that are recommended in the
guidelines. This should include a discussion on the appropri-
ate order of sequential treatment with available therapies and
the role of “drug holidays.”
Clinical standard 13Assessment of adherence to pharmacolog-
ical treatments that are recommended in new or revised osteo-
porosis clinical guidelines should be undertaken on an ongoing
basis after initiation of therapy, and appropriate corrective ac-
tion be taken if treated individuals have become non-adherent.
Clinical standard 14 New and revised osteoporosis clinical
guidelines should provide a commentary on recommended
non-pharmacological interventions, such as exercise and nu-
trition (including dietary calcium intake) and other non-
pharmacological interventions (e.g., hip protectors).
Clinical standard 15 In collaboration with the patient, the
treating clinician (hospital specialist and/or primary care pro-
vider) should develop a long-term management plan that pro-
vides recommendations on pharmacological and non-
pharmacological interventions to improve bone health and,
where appropriate, measures to reduce falls risk.
Clinical standard 16 New or revised osteoporosis clinical
guidelines should provide a commentary on what quality met-
rics should be in place to assess adherence with guideline-
based care.
Levels of attainment for clinical standard 16:
& Level 1: Conduct a local “pathfinder audit” in a hospital or
primary care practice to assess adherence to APCO
Framework clinical standards 1–9, 13, and 15.
& Level 2: Contribute to a local fracture/osteoporosis
registry.
& Level 3: Contribute to a fracture/osteoporosis registry for
your country or region.
The clinical standards are shown in Appendix 3.
Discussion
The 5IQ analysis of the multiple clinical practice guidelines on
osteoporosis from Asia-Pacific countries and regions con-
firmed our understanding, based on previous anecdotal re-
ports, that existing guidelines were markedly heterogeneous
in terms of their scope and recommendations. The findings
enabled APCO members to prioritize and select elements
through the Delphi consensus method. The resulting
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minimum standards for care for the Asia-Pacific region are
relevant, pragmatic, and feasible to implement.
Application of the Framework to clinical practice
guidelines
Clinicians need information that is clear and readily accessi-
ble. Osteoporosis guidelines should clearly articulate which
individuals should be identified for assessment, the investiga-
tions that should be offered, appropriate indications for treat-
ment, the pharmacological treatments and other interventions
that should be offered to specific patient groups, information
on self-management that should be provided to patients, how
the levels of healthcare systems should be integrated to ensure
seamless care, and how the quality of osteoporosis healthcare
services should be monitored and improved.
APCO’s goal is that all new or revised clinical practice
guidelines for prevention, diagnosis, and management of os-
teoporosis in the Asia-Pacific region will:
& be consistent with the scope proposed in the Framework,
& promote the standards of care recommended in the
Framework, and
& recommend local benchmarking against the standards rec-
ommended in the Framework.
To achieve this, APCO members will identify opportuni-
ties in their individual countries and regions to share the
Framework with colleagues and organizations involved in
clinical practice guideline development. The clinical standards
will be distributed in a modular format that should allow easy
adoption at the individual health care facility, national or re-
gional level.
Benchmarking and audit activities
Benchmarking against specific clinical standards is already
used to measure the performance of osteoporosis care.
Benchmarking of care for secondary prevention of fragility
fractures is a component of the IOF Capture the Fracture®
program [40], and of national fracture liaison service stan-
dards based on the 5IQ model [7–9]. Hip fracture registries,
that have been established in several countries, also enable
benchmarking of acute perioperative care and secondary frac-
ture prevention after hip fracture [41–46].
After the Framework is published and it is disseminated,
audit against benchmarks derived from the Framework will be
undertaken at various healthcare system levels, ranging from
individual healthcare provider or primary care medical prac-
tice level to hospital units, groups of hospitals, regions, or
nations. The scale of activities can range from audit based
on one selected standard to audit against several standards.
Initially, APCO members will be invited to undertake
“pathfinder audits” in their hospitals to establish baseline
levels of adherence with selected standards, such as BMD
testing rates and osteoporosis treatment initiated during the
episode of care. Follow-up audits will be conducted 12
months later tomeasure effects of implementing the standards.
Recently established and emerging themes in
osteoporosis care
Several developments that significantly impact strategies for
the management of osteoporosis have recently been brought to
the forefront of medical management of osteoporosis.
Predictably, the 5IQ analysis found that these were either
not incorporated into existing guidelines or mentioned only
briefly. However, they have enormous implications and po-
tential to change the treatment landscape of osteoporosis and
therefore need to be highlighted.
These include but are not limited to:
& systematic integration of case identification and manage-
ment at all levels of health systems, including acute care
services, when patients present with fractures (e.g.,
through FLSs),
& stratification of individual fracture risk,
& the role of sequential therapies, and
& the use of health economics to inform intervention thresh-
olds and indications for specific classes of osteoporosis
therapies.
Fracture liaison services
Up to 50% of patients with a hip fracture have already
sustained fractures at other skeletal sites during the previous
months or years [47, 48]. A prior fracture at any site is asso-
ciated with a doubling of future fracture [49, 50] and mortality
[51] risks. Accordingly, these “signal” or “sentinel” fractures
should alert healthcare providers to the opportunity for sec-
ondary fracture prevention.
Over the past decade and a half, coordinated post-fracture
models of care have been designed to ensure that healthcare
providers consistently respond to the first fracture to prevent
the second and subsequent fractures [48]. These are generally
hospital-based, but involvement of primary care physicians is
also important to ensure continuity of care [52, 53].
Components of effective FLSs include multidisciplinary in-
volvement, dedicated case managers and clinician champions,
regular assessment and follow-up, multifaceted interventions,
and patient education [54].
Fracture liaison service programs significantly increase
rates of BMD testing, initiation of osteoporosis treatment, ad-
herence to treatment, and reduce refracture incidence and
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mortality rates, compared with usual care [54, 55]. They are
cost-effective in comparison with usual care or no treatment,
regardless of the program intensity or the country [55]. The
IOF strongly promotes the concept of FLSs through its global
Capture the Fracture® initiative [40]. This initiative has set an
international benchmark for FLSs by defining 13 globally
endorsed standards for service delivery.
Fracture liaison services in the Asia-Pacific and reference
to these in the extant guidelines
The number of FLSs in the Asia-Pacific region is rapidly
increasing. Analyses of indigenous fracture liaison programs
have been conducted in several countries and regions in the
Asia-Pacific region including Australia [56], China [57, 58],
Chinese Taipei [59], Hong Kong SAR [60], Singapore [61],
Japan [62–64], New Zealand [65], South Korea [66–69], and
Thailand [70]. In 2017, the fracture liaison service consensus
meeting held in Taipei concluded that the 13 Best Practice
Framework Standards of the IOF’s Capture the Fracture®
campaign [40] were generally applicable in the Asia-Pacific
region (albeit with minor modifications). As of 17 September
2020, 111 FLSs from the Asia-Pacific region are included on
the IOF Global Map of Best Practice (https://www.
capturethefracture.org/map-of-best-practice). Eighty-four
have been fully evaluated, of which 19 have been awarded a
Gold star. These include FLSs from Australia, Japan, New
Zealand, Singapore, Taiwan, and Thailand.
Despite this burgeoning interest, the 5IQ analysis revealed
that only four guidelines in the Asia-Pacific region advocated
the role of FLSs, suggesting that the crucial role of secondary
fracture prevention is still sadly under-recognized among
guideline developers and policy makers in the Asia-Pacific
[52]. Two recent initiatives are, however, expected to enable
more widespread adoption of FLSs in the region: the FLS tool
box for Asia-Pacific developed by the Asia-Pacific Bone
Academy Fracture Liaison Service Focus Group [71], and the
Capture the Fracture® Partnership launched by the IOF (https://
www.capturethefracture.org/capture-fracture-partnership),
which includes several countries in the Asia Pacific region.
Risk stratification
Upon the knowledge that “fractures beget fractures” [47, 49,
50] has subsequently come the understanding that the risk of a
subsequent fragility fracture is particularly acute immediately
after the sentinel or the index fracture and that this risk wanes
progressively with time [72–78]. This very high fracture risk
in the 1 to 2 years after the index fracture has been termed
“imminent risk” [79, 80] and appears to be age-dependent,
with the transient effect of increased risk being more evident
at older ages [76]. The ratio of 10-year fracture probability
after a recent fragility fracture to that after a fracture,
irrespective of its site or recency, has been termed the proba-
bility ratio or adjustment ratio. Probability ratios that provide
adjustments to conventional FRAX® estimates for recency of
sentinel fractures have now been derived, though how they
will be included in the FRAX® algorithm is still being debat-
ed [81].
Other factors can also contribute to, or result in, a very high
fracture risk. The simultaneous presence of multiple risk factors
(e.g., family history of fracture, glucocorticoid use) can addi-
tively contribute to fracture probabilities and shift fracture risk
categories to higher strata of risk [30]. Individuals have also
been somewhat arbitrarily designated as very high risk if they
have fractures while on approved osteoporosis therapy, have
multiple prevalent fractures or fractures while on drugs causing
skeletal harm such as glucocorticoids, have very low T-score
(e.g., < − 3.0), have high risk for falls or a history of falls, or
have a FRAX® probability for major osteoporosis fracture >
30%, or hip fracture > 4.5% over a 10-year period [82].
This concept of stratification of osteoporotic fracture risk
that may enable or guide the choice of therapeutic agent is
gaining traction globally. Those at higher risk may require ini-
tiation of treatment with more potent therapies such as an ana-
bolic agent. For those at low risk, a decision will need to be
made on whether therapy with an anti-osteoporosis agent is
even indicated. Updated position papers and guidelines pub-
lished by the European Society for Clinical and Economic
Aspects of Osteoporosis (ESCEO) and the International
Osteoporosis Foundation (IOF) [80] and by the American
Association of Clinical Endocrinologists (AACE) [82] provide
recommendations for this stratification of risk. The ESCEO/
IOF position paper applies age-specific thresholds to define
high versus very high risk, while the AACE guidelines suggest
an arbitrarily decided fixed threshold as well as the presence of
certain pre-defined risk factors as described previously [80, 82].
At a regional and national level, these recommendations
will have to be reviewed to determine the relevance to local
practices and to see whether they offer tangible benefits to
patients. Some challenges to implementation of these guide-
lines in the Asia-Pacific would need to be considered. The
FRAX® thresholds that are recommended in the AACE
guidelines are likely only applicable to the USA. While
FRAX® has been validated in many Asian countries, most
of them have not implemented specific intervention thresholds
for use yet. Recommendations also need to consider local
reimbursement criteria, which often dictate eligibility criteria
for pharmacological treatment options.
Sequential therapies in osteoporosis
Osteoporosis is a chronic condition. Therefore, patients with
osteoporosis need a long-term, personalized management plan,
with many patients requiring multiple anti-osteoporosis medi-
cations during their lifetime. The specific and individualized
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treatment plan traditionally has involved initiation of therapy
with an antiresorptive agent. Most of the extant guidelines in
theAsia-Pacific region also favor this approach. However, there
is evidence for a stronger anti-fracture efficacy of bone-forming
treatments compared to antiresorptive ones from two clinical
trials in patients with severe osteoporosis [83, 84] and for a
blunted/delayed BMD response to bone-forming treatment,
with prior antiresorptive use, though this effect somewhat de-
pends on the potency of the antiresorptive agent [85–87].
In certain scenarios, a deleterious effect on BMD is seen in
patients previously treated with antiresorptive agents who are
then switched to an anabolic agent [88]. In contrast, sequential
therapy with an anabolic agent followed by an antiresorptive
agent appears largely to be associated with maintenance or
continued increase in BMD [88] and continued reduction in
fractures [84, 89].
This has resulted in increasing interest in sequential treat-
ment with an anabolic agent given as first-line treatment in the
very-high-risk fracture patient, whose fracture risk needs to be
addressed quickly and in whom BMD needs to be improved
quickly and as much as possible. However, the fact that this
may not always be possible, due to restrictions in reimburse-
ment criteria and limitations imposed by guidelines, should be
considered before advocating large-scale adoption of such
recommendations.
Health economics
Health economic analysis is playing an increasingly important
role to inform the relative value of osteoporosis therapies and
to help determine how best to allocate finite health care re-
sources. The development of absolute fracture risk–based as-
sessment and intervention thresholds has led also to the ex-
ploration of cost-effectiveness of interventions along the lines
of fracture probability. A significant body of evidence now
exists to show that anti-osteoporosis therapies are cost-
effective in women at high risk of fracture [90].
However, the cost-effectiveness of various pharmacologi-
cal therapies is determined in part by the costs and benefits of
treatment. Intervention thresholds will also vary, since they
depend critically on country- and region-specific factors such
as reimbursement issues, health economic assessment, will-
ingness to pay for healthcare, and access to DXA scanning.
Due to this vast heterogeneity in epidemiologic and economic
characteristics between countries, such thresholds should be
country-specific. In the USA, a 10-year absolute hip fracture
probability of 3% and its equivalent major osteoporotic frac-
ture probability of 20% have been considered as cost-effective
intervention thresholds [39]. Various other major osteoporotic
fracture risk fixed intervention thresholds ranging from 7 to
15% have been deemed to be cost-effective in other countries
[91, 92]. In the UK, age-dependent FRAX®-based
intervention thresholds have been shown to provide clinically
appropriate access to treatment as well as to be cost-effective
[93].
Given the evidence supporting initial treatment of patients
at very high risk of fragility fracture with an anabolic agent
followed by consolidating the effect of these agents with
antiresorptive agents, health economic appraisals exploring
the cost-effectiveness of such sequential therapies are also
slowly emerging [94].
Health economic evaluation studies in osteoporosis are few
in the Asia-Pacific region. Robust studies have been conducted
in a few countries including Singapore [95], China [96, 97],
Japan [98, 99], and Australia [100]. These studies have
employed different modeling strategies and have explored
cost-effectiveness of fracture intervention thresholds as well
as of various osteoporosis medications. The varying results
obtained from these studies highlight the crucial differences in
economic, epidemiological, and clinical practice factors be-
tween the countries in the vast region that is the Asia-Pacific.
Conclusions
The APCO Framework represents the first consensus min-
imum standards of osteoporosis care, purpose-developed
by clinicians for the whole of the Asia-Pacific region.
Developing it through a comparative analysis of extant
guidelines in the Asia Pacific region and through the con-
sensus of experts from diverse health care systems enables
the recommendations to be practical and relevant to the
unique needs of this vast and populous region. However,
publishing and disseminating the Framework is only half
the battle won. The success of the Framework will be
discernible only after the standards have been implement-
ed throughout the region and its efficacy has been system-
atically measured.
The Framework provides accessible, clear, and feasible rec-
ommendations for osteoporosis care in the Asia Pacific region. It
is hoped that the Framework will inform national societies,
guideline development authorities, and health care policy makers
in the development of new guidelines and promote the revision
of existing guidelines. The principles and processes behind its
development can be translated and adapted to other regions of the
world that also face similar socioeconomic diversity and hetero-
geneity of healthcare resources. The implementation of the
Framework, or similar sets of standards of care inspired by it, is
thus expected to significantly reduce the burden of osteoporosis,
not only in the Asia Pacific region, but also globally.
Emerging concepts in osteoporosis care and technologies
should also be keenly followed and should be incorporated
into new and revised guidelines after careful deliberation on
their applicability to local health care practices.
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Appendix 1 Template for extracting data
from clinical practice guidelines (modified
5IQ model)




4. Number of pages
5. Review date
6. Guideline published in English (Yes/No)
7. Corresponding author (Yes/No)
8. Does the guideline include a flowchart/algorithm?
Identification
1. Male, female, both male and female
2. Individuals who have sustained fragility fractures a. Age threshold
b. Fracture types evaluated
c. Other comments relating to secondary fracture
prevention
3. Individuals takingmedicines tomanage other conditions which are associated with bone loss
and/or increased fracture risk:[10]







h. Proton pump inhibitors
i. Selective serotonin reuptake inhibitors
j. Thiazolidinediones
k. Other medicines
4. Conditions associated with bone loss and/or increased fracture risk:[10] a. Chronic obstructive pulmonary disease
b. Diabetes







5. Other risk factors a. Age 70 years or over
b. Early menopause
c. Excessive alcohol intake
e. Family history
f. Height loss
g. Low body mass index/weight
h. Prolonged immobility
i. Smoking
j. Other risk factors
k. Other comments on identification
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(continued)
Publication information and format
Investigation
1. BMD testing, if available
2. Fracture risk calculators a. FRAX®
b. Garvan






3. Vertebral fracture assessment by X-Ray or DXA
4. Falls risk assessment









6. Referral to specialist
Information
1. Information on calcium intake
2. Information relating to sun exposure
3. Information relating to osteoporosis and fracture risk
4. Information relating to exercise
5. Other information
Intervention
1. Which patient groups are indicated for treatment? a. Hip fracture
b. Vertebral fracture
c. Non-hip, non-vertebral fracture
d. BMD T-Score ≤ –2.5 SD
e. Osteopenia + FRAX ≥3% Hip or ≥ 20% MOF
f. Osteopenia + RFs or eligible by OSTA or SCORE
g. Osteopenia + ≥10 years postmenopausal
h. FRAX or Garvan ≥3% Hip or ≥ 20% MOF
i. Eligible by OSTA, MORES or SCORE
j. QCT <80 mg/cm3
k. Height loss >4 cm
l. Androgen deprivation therapy use
m. Aromatase inhibitor use
n. Glucocorticoid use
2. Which treatment options are recommended? a. Bisphosphonates (oral, IV)
b. Calcium
c. HRT
d. Monoclonal antibodies (denosumab, romosozumab)
e. Parathyroid hormone analogues (abaloparatide,
teriparatide)
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Appendix 2 Delphi Round 1 questionnaire
toward consensus on clinical standards
for osteoporosis
(continued)
Publication information and format
f. Selective estrogen receptor modulators (raloxifene.
tamoxifen. toremifene)
g. Vitamin D
h. Other treatment options
3. Are recommendations made on monitoring treatment?
4. Are recommendations made on treatment duration?
5. Are recommendations made on checking adherence with treatment?
6. Comments on side effects
7. Comments on referral to falls prevention programs
8. Comments relating to other interventions
Integration
1. Are recommendations made to provide the patient with a long-term management plan?
2. Are recommendations made to provide the patient’s primary care provider with a long-term management plan?
Quality
1. Does the guideline advocate audit of care provision against clinical care standards?
2. Does the guideline advocate healthcare providers maintain ongoing professional medical education relating to osteoporosis?
Domain 1: Notable findings from the 5IQ Comparative analysis of osteoporosis clinical guidelines from across the Asia Pacific region
This domain of the questionnaire includes a series of open-ended questions which invite you to share your opinions on the most notable findings of the
5IQ analysis report.
5IQ item Question Options
Identification Considering the groups of individuals that the various guidelines recommend should be identified for
bone health assessment, what are the most notable findings in the analysis? (You can indicate more
than one)
[Free text]
Investigation Considering the investigations that the various guidelines recommend should be undertaken, what are
the most notable findings in the analysis?
[Free text]
Information Considering the types of information that should be imparted to patients to engage them in their care,
which are the most notable points identified by the analysis in your view?
[Free text]
Intervention Considering the indications for treatment that are advocated, what are the most notable findings
identified by the analysis in your view?
[Free text]
Considering the pharmacological treatments for specific patient groups identified by the analysis, what
are the most notable findings in your view?
[Free text]
Considering the findings of the analysis related to falls prevention, what are the most notable in your
view?
[Free text]
Integration Considering how integration should occur between primary and secondary care, what are the most
notable findings identified by the analysis in your view?
[Free text]
Quality Considering the findings of the 5IQ Comparative analysis related to quality metrics, what are the most
notable findings in your view?
[Free text]
Domain 2: How should the Framework be structured?
How do you envisage the Framework being structured? Would you like to have it as a simple list of standards or have




Domain 3: What clinical standards are required?
This domain seeks your opinions on what specific aspects of care merit having a clinical standard. We invite you to rate the importance or not of having
particular standards and invite you to add any comments as free text.
5IQ item Question Options




Not at all important
How important is it to have a standard relating to identification of individuals with common risk factors
for osteoporosis (e.g. age 70 years or over, early menopause, excessive alcohol intake, family history,





Not at all important
How important is it to have a standard relating to identification of individuals who take medicines





Not at all important
How important is it to have a standard relating to identification of individuals with conditions associated





Not at all important






Not at all important




Not at all important






Not at all important
How important is it to have a standard relating to How important is it to have a standard relating to






Not at all important






Not at all important




Not at all important
Information How important is it to have a standard relating to what information should be imparted to patients to
engage them in their care (e.g. information on calcium intake, sun exposure, the relationship between





Not at all important
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(continued)
Intervention The 5IQ analysis identified a broad range of indications for treatment, as listed below. In your opinion,
which of the following indications for treatment should feature in osteoporosis clinical guidelines?
Please indicate in priority order (where number 1 is the highest priority). Only provide rankings for those
indications which you believe should be included.
[ ] Hip fracture
[ ] Vertebral fracture
[ ] Non-hip, non-vertebral fracture
[ ] BMD T-Score ≤ –2.5 SD
[ ] Osteopenia + FRAX® ≥3% Hip or ≥ 20% MOF
[ ] Osteopenia + RFs or eligible by OSTA or SCORE
[ ] Osteopenia + ≥10 years postmenopausal
[ ] FRAX® or Garvan ≥3% Hip or ≥ 20% MOF
[ ] Eligible by OSTA, MORES or SCORE
[ ] QCT <80 mg/cm3
[ ] Height loss >4 cm
[ ] Androgen deprivation therapy use
[ ] Aromatase inhibitor use
[ ] Glucocorticoid use
[ ] Country-specific thresholds
[Select items and rank
according to priority]
How important is it to have a standard relating to which pharmacological treatments should be





Not at all important






Not at all important






Not at all important




Not at all important




Not at all important




Not at all important




Not at all important
Integration How important is it to have a standard relating to provision of a long-term management plan to the





Not at all important
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Appendix 3 The APCO Framework
Clinical standards Levels of attainment
(where applicable)
1 Men and women who sustain a fragility fracture should be systematically
and proactively identified to undergo assessment of bone health and,
where appropriate, falls risk.
1. Individuals who sustain hip fractures should be identified.
2: Individuals who sustain hip and/or clinical vertebral fractures should
be identified.
3: Individuals who sustain hip, clinical and/or morphometric vertebral,
and/or non-hip, non-vertebral major osteoporotic fractures should be
identified.
2 Men and women with common risk factors for osteoporosis should be
proactively identified to undergo assessment of bone health and,
where appropriate, falls risk. A sex-specific age threshold for
assessment should be determined for each country or region and
should be included in new or revised osteoporosis clinical guidelines.
3 Men and women who take medicines that are associated with bone loss
and/or increased fracture risk should be proactively identified to
undergo assessment of bone health and, where appropriate, falls risk.
A commentary should be included in new or revised osteoporosis
clinical guidelines to highlight commonly used medicines that are
associated with bone loss and/or increased fracture risk.
4 Men and women who have conditions associated with bone loss and/or
increased fracture risk should be proactively identified to undergo
assessment of bone health. A commentary should be included in new
or revised osteoporosis clinical guidelines to highlight common
prevalent conditions in the country or region.
5 The use of country-specific (if available) fracture risk assessment tools
(e.g. FRAX®, Garvan, etc.) or osteoporosis screening tools (e.g.
OSTA) should be a standard component of investigation of an
individual’s bone health and prediction of future fracture risk and/or
osteoporosis risk.
6 Assessment for presence of vertebral fracture(s) either by X-ray (or other
radiological investigations such as CT or MRI), or by DXA-based
VFA should be a standard component of investigation of osteoporosis
and prediction of future fracture risk.
1. Individuals presenting with clinical vertebral fractures should undergo
assessment for osteoporosis.
2. Individuals with incidentally detected vertebral fractures on X-ray
and/or other radiological investigations should be assessed for
osteoporosis.
3. Individuals being a ssessed for osteoporosis should undergo spinal
imaging with X-ray or other appropriate radiological modalities, or
with DXA-based VFA.
7 A falls risk assessment should be a standard component of investigation
of an individual’s future fracture risk.
8 In order to engage individuals in their own care, information should be
provided on calcium and vitaminD intake, sun exposure, exercise, and
the relationship between osteoporosis and fracture risk.
9 The decision to treat with osteoporosis-specific therapies and the choice
of therapy should be informed as much as possible by country-specific
and cost-effective intervention thresholds. Intervention thresholds that
can be considered include:
(continued)
Quality How important is it to have a standard relating to what quality metrics should be in place to assess





Not at all important
General
Do you have any other comments related to the development of the Framework clinical standards? [Free text]
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